公开(公告)号：EP2205256A2

公开(公告)日：2010-07-14

申请号：EP08833980.9

申请日：2008-09-26

申请人： Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College ,  Massachusetts Institute of Technology ,  HOWARD HUGHES MEDICAL INSTITUTE

发明人： REINHERZ, Ellis L. ,  KIM, Mikyung ,  WAGNER, Gerhard ,  SUN, Zehn-Yu J. ,  OH , Kyoung Joon ,  IRVINE, Darrell, J. ,  BERSHTEYN, Anna

IPC分类号： A61K38/00 ,  A61K9/16

CPC分类号： A61K38/10 ,  A61K9/127 ,  A61K9/5123 ,  A61K9/5153 ,  A61K38/162 ,  A61K39/12 ,  A61K39/21 ,  A61K47/6907 ,  A61K47/6911 ,  A61K47/6913 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/6018 ,  C07K16/1063 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/90 ,  C12N2740/16134

摘要： The present disclosure relates to reagents (antigenic and/or immunogenic reagents) and kits that are useful in a variety of in vitro, in vivo, and ex vivo methods including, e.g., methods for inducing an immune response, or for generating an antibody, in a subject. The reagents described herein can be used in the treatment or prevention of HIV-1 infections. In addition, the disclosure provides methods and compositions useful for designing (or identifying) an agent that binds to an membrane proximal external region (MPER) of an HIV-1 gp160 polypeptide or an agent that inhibits the fusion of an HIV-1 particle to a cell.